Paper Details
- Home
- Paper Details
Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Author: JiangLan, JiangXiaoxiao, KouXinhui, LinZhaohu, LiuHongrui, LiuHuijuan, LiuLongkai, SunFanghui, WangXuan, YangYonghua
Original Abstract of the Article :
Since the lack of targeted treatment, triple-negative breast cancer (TNBC) has poor outcomes. Histone deacetylase inhibitors (HDACi) blocking the activity of specific HDACs have emerged as cancer therapeutic agents. However, the therapeutic efficiency is still not satisfactory for patients with soli...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.ejphar.2017.08.022
データ提供:米国国立医学図書館(NLM)
Vorinostat and Simvastatin: A Synergistic Duo Against Triple-Negative Breast Cancer
This research explores the potential of combining vorinostat, a histone deacetylase inhibitor (HDACi), with simvastatin, a statin drug, to combat triple-negative breast cancer (TNBC). The study investigates the synergistic effects of this combination on TNBC cells, examining their impact on cell proliferation, apoptosis, and autophagic processes. The authors delve into the underlying mechanisms of this combination, focusing on the role of Rab7 prenylation in regulating autophagosome-lysosome fusion. Their findings suggest that this combination holds promise as a novel therapeutic approach for TNBC.A Powerful Combination Against TNBC
The research demonstrates that the combination of vorinostat and simvastatin exhibits potent synergistic effects in inducing apoptosis in TNBC cells. The combination disrupts autophagic processes by inhibiting Rab7 prenylation, leading to the accumulation of autophagosomes and enhanced cell death. These findings suggest that this combination could significantly improve treatment outcomes for patients with TNBC.Unlocking New Avenues for TNBC Treatment
This study opens a new avenue for TNBC treatment by highlighting the synergistic potential of vorinostat and simvastatin. The research provides valuable insights into the complex interplay between autophagy and apoptosis, offering a novel approach to targeting TNBC cells. The findings underscore the importance of exploring drug combinations to enhance therapeutic efficacy and overcome the challenges of treating this aggressive form of breast cancer.Dr.Camel's Conclusion
This research is like a shimmering oasis in the vast desert of cancer research, offering a promising new approach to combating TNBC. The synergistic effects of vorinostat and simvastatin highlight the power of combining different therapeutic strategies to achieve greater impact. It’s a reminder that even in the face of adversity, there’s always a chance to find new solutions and create a brighter future.Date :
- Date Completed 2018-05-02
- Date Revised 2021-12-04
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.